TLDR Nate Geraci stated that the market is underestimated the demand for an XRP ETF. He compared current doubts on XRP ETF demand to early skepticism about Bitcoin and Ethereum ETFs. The SEC is reviewing ninety-two crypto ETF filings, including seven for XRP and eight for Solana. WisdomTree saw its XRP ETF decision delayed in [...] The post XRP ETF Filings Grow as Expert Nate Geraci Predicts Strong Investor Demand appeared first on CoinCentral.TLDR Nate Geraci stated that the market is underestimated the demand for an XRP ETF. He compared current doubts on XRP ETF demand to early skepticism about Bitcoin and Ethereum ETFs. The SEC is reviewing ninety-two crypto ETF filings, including seven for XRP and eight for Solana. WisdomTree saw its XRP ETF decision delayed in [...] The post XRP ETF Filings Grow as Expert Nate Geraci Predicts Strong Investor Demand appeared first on CoinCentral.

XRP ETF Filings Grow as Expert Nate Geraci Predicts Strong Investor Demand

TLDR

  • Nate Geraci stated that the market is underestimated the demand for an XRP ETF.
  • He compared current doubts on XRP ETF demand to early skepticism about Bitcoin and Ethereum ETFs.
  • The SEC is reviewing ninety-two crypto ETF filings, including seven for XRP and eight for Solana.
  • WisdomTree saw its XRP ETF decision delayed in August while other major managers filed amendments with October deadlines.
  • Canary Capital described XRP as the only digital asset besides Bitcoin that resonates with Wall Street professionals.

The debate on an XRP ETF has shifted after Nate Geraci dismissed overblown doubts about investor demand. He stated comparisons with Bitcoin and Ethereum ETFs reveal the same early skepticism. His remarks come as the U.S. Securities and Exchange Commission faces a crowded calendar of crypto fund filings.

Bitcoin and Ethereum ETFs Set a Pattern

Nate Geraci reminded that Bitcoin ETFs once faced doubt before billions of dollars entered the market. He argued Ethereum ETFs repeated the same cycle, with critics underestimating demand until strong inflows followed. “People thought small before, and they were wrong twice,” Geraci said, highlighting the historic misjudgments.

Moreover, he suggested the XRP ETF could follow this identical trajectory if regulators grant approval. The market already demonstrated resilience when opportunities became accessible through regulated funds. Thus, institutions may respond strongly once another major asset joins the approved list.

In addition, the SEC currently handles 92 crypto ETF filings across multiple assets. While Bitcoin and Ethereum gain new products, altcoins show rising interest. Therefore, speculation about XRP ETF demand directly fits into this broader momentum.

XRP ETF Filings Gain Institutional Backing

According to official trackers, seven XRP ETF filings now sit with the SEC. These include heavyweight managers and amendments scheduled with October deadlines. Notably, WisdomTree saw its XRP ETF decision delayed on August 25, adding to the anticipation.

The activity indicates growing seriousness rather than small-scale experimentation. Large firms rarely submit filings without confidence in regulatory or institutional traction. Consequently, these developments underline that XRP ETF speculation extends far beyond retail curiosity.

Furthermore, Amplify introduced a unique filing that focuses on generating income through XRP options. This model shows experimentation with diverse structures, signaling industry creativity. Similarly, Canary Capital named XRP alongside Bitcoin as the only assets with real Wall Street resonance.

Shifting Attention to Solana and XRP

Solana ETF filings reached eight, while XRP stands at seven. Both assets represent the leading non-Bitcoin, non-Ethereum entries. Therefore, they embody a shift in where fund issuers now direct energy.

This shift arrives as institutional investors explore diversification in digital assets. Established managers push filings because they expect eventual approval. Hence, the narrative is turning from possibility to probability.

Geraci’s voice reinforces this trend by dismissing speculation about low demand. He emphasized that skepticism missed reality in past ETF launches. If the SEC approves an XRP ETF, the market’s hesitation could end immediately.

The post XRP ETF Filings Grow as Expert Nate Geraci Predicts Strong Investor Demand appeared first on CoinCentral.

Market Opportunity
XRP Logo
XRP Price(XRP)
$2.0636
$2.0636$2.0636
-1.56%
USD
XRP (XRP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23